Comparing 2 hypotheses side-by-side
DNAJB6 specifically recognizes and suppresses amyloidogenic β-sheet conformations shared across tau, α-synuclein, and TDP-43 aggregates. Enhanced DNAJB6 expression or small molecule activators could provide broad-spectrum protection against cross-seeding by disrupting the common structural motifs that enable heterologous nucleation.
Transglutaminase-2 creates covalent cross-links between lysine and glutamine residues shared across tau, α-synuclein, and TDP-43, stabilizing heterologous aggregates. Selective TG2 inhibitors targeting the cross-seeding-specific substrate sites could disrupt mixed aggregate formation while preserving physiological TG2 functions.
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
| Dimension | HSP70 Co-chaperone DNAJB6 Univ | Transglutaminase-2 Cross-Linki |
|---|---|---|
| Mechanistic | 0.650 | 0.750 |
| Evidence | 0.450 | 0.600 |
| Novelty | 0.800 | 0.700 |
| Feasibility | 0.450 | 0.800 |
| Impact | 0.600 | 0.700 |
| Druggability | 0.350 | 0.850 |
| Safety | 0.400 | 0.650 |
| Competition | 0.800 | 0.750 |
| Data | 0.500 | 0.700 |
| Reproducible | 0.550 | 0.750 |
| KG Connect | 0.682 | 0.742 |
No evidence citations yet
No evidence citations yet
4 rounds · quality: 0.95
# Novel Therapeutic Hypotheses for Cross-Seeding in Neurodegeneration ## Hypothesis 1: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor **Description:** DNAJB6 specifically recognizes and ...
# Novel Therapeutic Hypotheses for Cross-Seeding in Neurodegeneration ## Hypothesis 1: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor **Description:** DNAJB6 specifically recognizes and ...
I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available. ## Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor **Specific Weaknesses:** - ...
I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available. ## Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor **Specific Weaknesses:** - ...
4 rounds · quality: 0.95
# Novel Therapeutic Hypotheses for Cross-Seeding in Neurodegeneration ## Hypothesis 1: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor **Description:** DNAJB6 specifically recognizes and ...
# Novel Therapeutic Hypotheses for Cross-Seeding in Neurodegeneration ## Hypothesis 1: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor **Description:** DNAJB6 specifically recognizes and ...
I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available. ## Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor **Specific Weaknesses:** - ...
I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available. ## Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor **Specific Weaknesses:** - ...
Curated mechanism pathway diagrams from expert analysis
graph TD
A["Misfolded Protein Seeds"] --> B["alpha-Synuclein Aggregation"]
A --> C["Tau Fibrillization"]
A --> D["TDP-43 Inclusion Formation"]
B --> E["Cross-Seeding Between Proteins"]
C --> E
D --> E
E --> F["Amplified Aggregate Toxicity"]
F --> G["Neurodegeneration Spread"]
H["DNAJB6 Co-chaperone"] --> I["J-Domain Binds HSP70"]
I --> J["HSP70 ATPase Activation"]
J --> K["Substrate Recognition"]
K --> L["Bind Amyloid Nuclei"]
L --> M["Block Fibril Elongation"]
L --> N["Prevent Cross-Seeding"]
O["DNAJB6 Upregulation Therapy"] --> P["Enhanced DNAJB6 Expression"]
P --> Q["Increased HSP70 Recruitment"]
Q --> R["Universal Anti-Aggregation"]
R --> S["Inhibit alpha-Syn Fibrillization"]
R --> T["Inhibit Tau Aggregation"]
R --> U["Inhibit TDP-43 Inclusions"]
S --> V["Pan-Neurodegenerative Protection"]
T --> V
U --> V
style A fill:#4a1942,stroke:#ce93d8,color:#e0e0e0
style H fill:#1a3a4a,stroke:#4fc3f7,color:#e0e0e0
style R fill:#1a3a2a,stroke:#81c784,color:#e0e0e0
style V fill:#2a3a1a,stroke:#c5e1a5,color:#e0e0e0
graph TD
A["""Neuroinflammation
& Calcium Dysregulation"""] -->|"Ca2+ Influx"| B["TG2 Activation
(Transglutaminase-2)"]
B -->|"Isopeptide Bond
Formation"| C["Tau Cross-Linking
& Aggregation"]
B -->|"Protein Cross-Linking"| D["Abeta Oligomer
Stabilization"]
B -->|"ECM Cross-Linking"| E["BBB Disruption
& Matrix Stiffening"]
B -->|"NF-kappaB Activation"| F["Pro-inflammatory
Cytokine Cascade"]
C --> G["Neurofibrillary
Tangle Formation"]
D --> H["Amyloid Plaque
Stabilization"]
E --> I["Peripheral Immune
Cell Infiltration"]
F --> J["Chronic
Neuroinflammation"]
G --> K["Neuronal Death
& Cognitive Decline"]
H --> K
I --> J
J --> K
L["""TG2 Inhibitor
Therapy"""] -->|"Selective Active-Site
Blockade"| M["TG2 Cross-Linking
Inhibition"]
M -->|"Reduced Tau
Cross-Linking"| N["Prevented Tangle
Formation"]
M -->|"Reduced Abeta
Stabilization"| O["Enhanced Abeta
Clearance"]
M -->|"Preserved BBB
Integrity"| P["Reduced Immune
Infiltration"]
M -->|"Suppressed NF-kappaB"| Q["Reduced
Neuroinflammation"]
N --> R["Neuroprotection &
Cognitive Preservation"]
O --> R
P --> R
Q --> R
style A fill:#ff8a80,stroke:#d32f2f,color:#000
style L fill:#4fc3f7,stroke:#2196f3,color:#000
style R fill:#81c784,stroke:#4caf50,color:#000
style K fill:#ffab91,stroke:#e64a19,color:#000